Autolus Limited clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   BOBCAT · Obe-cel in Refractory Progressive Forms of Multiple…BOBCAT · Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

   Enrollment increased: 18 → 24 participants

   Autolus Limited·Phase 1· NCT07139743· Registry history of NCT07139743 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Minor

   CD19 Targeted CAR T Cell Therapy · Relapsed or Refractory B Cell…CD19 Targeted CAR T Cell Therapy · Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

   Trial sites expanded: 11 → 14 locations

   Autolus Limited·Phase 1· NCT06173518· Registry history of NCT06173518 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.